CIA-Linked Investor Helped Quantum Systems Expand in US 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
OpenAI Rejects Apple Trade Secret Theft Claims 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
EDEN PRAIRIE, Minn., March 13, 2018 -- CHF Solutions, Inc. (Nasdaq:CHFS) announces today that its fourth quarter and year-end 2017 financial results will be released on Tuesday, March 20, 2018. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company's financial results and provide a general business overview.
To access the live webcast, please visit the Investors page of the CHF Solutions website at www.chf-solutions.com or access the webcast directly at https://edge.media-server.com/m6/p/dxgvnn8x. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID 9684909. An audio archive of the webcast and the call script will be available following the call on the Investor page at www.chf-solutions.com.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
